Obsidian Therapeutics Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
104
- Stock Symbol
-
OBX
- Investments
-
1
- Share Price
-
$12.44
- (As of Thursday Closing)
Obsidian Therapeutics General Information
Description
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.
Contact Information
Website
www.obsidiantx.comCorporate Office
- 1030 Massachusetts Avenue
- Cambridge, MA 02138
- United States
Corporate Office
- 1030 Massachusetts Avenue
- Cambridge, MA 02138
- United States
Obsidian Therapeutics Timeline
Obsidian Therapeutics Stock Performance
As of 12-Nov-2026, Obsidian Therapeutics’s stock price is $12.44. Its current market cap is $771M with 61.8M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $12.44 | $12.88 | $9.60 - $49.97 | $771M | 61.8M | 496K |
Obsidian Therapeutics Financials Summary
As of 31-Mar-2026, Obsidian Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Mar-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| EBITDA | (97,898) | (104,183) | (89,728) |
| Net Income | (95,254) | (100,607) | (83,109) |
| Total Assets | 70,136 | 88,580 | 183,713 |
| Total Debt | 3,604 | 4,283 | 6,814 |
Obsidian Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Obsidian Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Obsidian Therapeutics Comparisons
Industry
Financing
Details
Obsidian Therapeutics Competitors (61)
One of Obsidian Therapeutics’s 61 competitors is Adaptimmune Therapeutics, a Formerly VC-backed company based in Abingdon, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Eureka Therapeutics | Venture Capital-Backed | Emeryville, CA | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA |
Obsidian Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Obsidian Therapeutics Patents
Obsidian Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026232030-A1 | Self-inactivating retroviral vector for engineering mb-il15-ca2 expressing til | Pending | 02-May-2025 | ||
| US-20260209773-A1 | Compositions and methods for tunable regulation of rnai | Pending | 21-Jan-2025 | ||
| WO-2026161343-A1 | Compositions and methods for tunable regulation of rnai | Pending | 21-Jan-2025 | ||
| US-20260115289-A1 | Low dose lymphodepletion with adoptive cell therapy | Pending | 31-Oct-2024 | ||
| WO-2026096805-A1 | Low dose lymphodepletion with adoptive cell therapy | Pending | 31-Oct-2024 | A61K31/433 |
Obsidian Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Obsidian Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Obsidian Therapeutics Acquisitions (1)
Obsidian Therapeutics’s most recent deal was a Merger/Acquisition with Galera Therapeutics for . The deal was made on 03-Aug-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Galera Therapeutics | 03-Aug-2026 | Merger/Acquisition | Drug Discovery |
Obsidian Therapeutics FAQs
-
When was Obsidian Therapeutics founded?
Obsidian Therapeutics was founded in 2015.
-
Where is Obsidian Therapeutics headquartered?
Obsidian Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Obsidian Therapeutics?
Obsidian Therapeutics has 104 total employees.
-
What industry is Obsidian Therapeutics in?
Obsidian Therapeutics’s primary industry is Drug Discovery.
-
Is Obsidian Therapeutics a private or public company?
Obsidian Therapeutics is a Public company.
-
What is Obsidian Therapeutics’s stock symbol?
The ticker symbol for Obsidian Therapeutics is OBX.
-
What is the current stock price of Obsidian Therapeutics?
As of 12-Nov-2026 the stock price of Obsidian Therapeutics is $12.44.
-
What is the current market cap of Obsidian Therapeutics?
The current market capitalization of Obsidian Therapeutics is $771M.
-
Who are Obsidian Therapeutics’s competitors?
Adaptimmune Therapeutics, Eureka Therapeutics, Ayala Pharmaceuticals, Kite Pharma, and CytomX Therapeutics are some of the 61 competitors of Obsidian Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
